Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. has reported promising secondary data from a Phase 2A trial of its psychedelic microdosing treatment for depression, revealing significant reductions in anxiety, stress, and depression symptoms, and an improved psychological quality of life. The treatment, MB22001, has demonstrated a 60% decrease in depressive symptoms with a favorable safety profile and no severe adverse events. These findings bolster MindBio’s position as a pioneer in the development of psychiatric medicines using microdoses of psychedelics.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
